Cargando…
Remdesivir appears to save costs in COVID-19 patients on low-flow oxygen therapy in Turkey
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377331/ https://www.ncbi.nlm.nih.gov/pubmed/34429577 http://dx.doi.org/10.1007/s40274-021-07961-9 |
Ejemplares similares
-
Baricitinib + remdesivir cost saving vs remdesivir for hospitalised COVID-19 patients in the USA
Publicado: (2021) -
Remdesivir may be cost saving in eligible patients during COVID-19 infections in Germany
Publicado: (2021) -
Cost-Effectiveness Analysis of Remdesivir Treatment in COVID-19 Patients Requiring Low-Flow Oxygen Therapy: Payer Perspective in Turkey
por: Oksuz, Ergun, et al.
Publicado: (2021) -
Remdesivir cost effective for severe COVID-19 in China
Publicado: (2021) -
Effects on LOS may not justify cost of remdesivir for severe COVID-19
Publicado: (2021)